CA3243584A1 - THERAGNOSTICS FOLATE CONJUGATES - Google Patents
THERAGNOSTICS FOLATE CONJUGATESInfo
- Publication number
- CA3243584A1 CA3243584A1 CA3243584A CA3243584A CA3243584A1 CA 3243584 A1 CA3243584 A1 CA 3243584A1 CA 3243584 A CA3243584 A CA 3243584A CA 3243584 A CA3243584 A CA 3243584A CA 3243584 A1 CA3243584 A1 CA 3243584A1
- Authority
- CA
- Canada
- Prior art keywords
- compound according
- compound
- radiometal
- folate
- dota
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22154652 | 2022-02-01 | ||
| EP22154652.6 | 2022-02-01 | ||
| PCT/EP2023/052117 WO2023148116A1 (en) | 2022-02-01 | 2023-01-30 | Theragnostic folate conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3243584A1 true CA3243584A1 (en) | 2023-08-10 |
Family
ID=80118841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3243584A Pending CA3243584A1 (en) | 2022-02-01 | 2023-01-30 | THERAGNOSTICS FOLATE CONJUGATES |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250127938A1 (enExample) |
| EP (1) | EP4472677A1 (enExample) |
| JP (1) | JP2025504027A (enExample) |
| KR (1) | KR20240146013A (enExample) |
| CN (1) | CN118647412A (enExample) |
| AU (1) | AU2023216406A1 (enExample) |
| CA (1) | CA3243584A1 (enExample) |
| IL (1) | IL314508A (enExample) |
| WO (1) | WO2023148116A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025227100A2 (en) * | 2024-04-26 | 2025-10-30 | Purdue Research Foundation | Targeted delivery of therapeutic agent to retinal pigment epithelium in treatment of ocular diseases |
-
2023
- 2023-01-30 AU AU2023216406A patent/AU2023216406A1/en active Pending
- 2023-01-30 US US18/834,636 patent/US20250127938A1/en active Pending
- 2023-01-30 WO PCT/EP2023/052117 patent/WO2023148116A1/en not_active Ceased
- 2023-01-30 EP EP23702012.8A patent/EP4472677A1/en active Pending
- 2023-01-30 CA CA3243584A patent/CA3243584A1/en active Pending
- 2023-01-30 KR KR1020247028652A patent/KR20240146013A/ko active Pending
- 2023-01-30 JP JP2024544930A patent/JP2025504027A/ja active Pending
- 2023-01-30 CN CN202380018495.8A patent/CN118647412A/zh active Pending
- 2023-01-30 IL IL314508A patent/IL314508A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118647412A (zh) | 2024-09-13 |
| WO2023148116A1 (en) | 2023-08-10 |
| US20250127938A1 (en) | 2025-04-24 |
| AU2023216406A1 (en) | 2024-09-19 |
| KR20240146013A (ko) | 2024-10-07 |
| EP4472677A1 (en) | 2024-12-11 |
| IL314508A (en) | 2024-09-01 |
| JP2025504027A (ja) | 2025-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7500551B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）の標識化阻害剤、画像化剤としてのそれらの使用、及びｐｓｍａ発現がんの処置のための医薬剤 | |
| ES2990974T3 (es) | Conjugados de folato de entidades fijadoras de albúmina | |
| CN109053616B (zh) | 前列腺特异性膜抗原(psma)的标记的抑制剂及其用途 | |
| ES2844586T3 (es) | Inhibidores del antígeno prostático específico de membrana (PSMA) etiquetados con 18F y su uso como agentes de obtención de imágenes para el cáncer de próstata | |
| CN113573742A (zh) | 新型肿瘤抗原结合剂及其用途 | |
| WO2014117001A1 (en) | Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides | |
| US20250108138A1 (en) | Theragnostic folate conjugates | |
| Ruser et al. | Synthesis and evaluation of two new bifunctional carboxymethylated tetraazamacrocyclic chelating agents for protein labeling with indium-111 | |
| KR101336071B1 (ko) | 암 진단용 ｍｒｉ／ｃｔ 이중 조영제 및 그 제조방법 | |
| US20250127938A1 (en) | Theragnostic folate conjugates | |
| HK40109744A (zh) | 治疗诊断学叶酸酯缀合物 | |
| HK40110380A (zh) | 治疗诊断学叶酸酯缀合物 | |
| JP2024530057A (ja) | ネトリン－１検出、コンパニオン検査及び放射線に基づく療法 | |
| JP2024519603A (ja) | 神経内分泌セラノスティクスのための前駆体および放射性トレーサー | |
| EP4640240A1 (en) | Peptide-based radiopharmaceuticals for non-invasive imaging of the functional liver reserve | |
| EP4282439A1 (en) | Radioisotope labeled sstr2-agonists with linkers | |
| JP7816883B2 (ja) | 線維症の診断および／またはモニタリングに使用するための化合物 | |
| KR20250011145A (ko) | 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드 | |
| HK40054611A (en) | Novel tumor antigen binding agents and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240731 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240801 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240801 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240801 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241002 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |